Skip to content
  • Home
  • Pipeline
  • Biology
  • Team
  • Investors
  • News & Events
CONTACT US

Tag: research & development

APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis

Presentation at IPF Summit Elucidates APT-101 Mechanism of Action

APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis

APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research

APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer

APIE Therapeutics appoints Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief business officer and chief medical officer, respectively.

APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer

APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.

Contact us to get more information about the company and the compelling nonclinical studies results that supports moving the program into human clinical trials.
CONTACT US
QUICK CONTACT
  • APIE Therapeutics
  • P.O. Box 13169 2 Davis Dr. RTP, NC 27709
  • +1 (919) 594-1985
  • info@apie-therapeutics.com
USEFUL LINKS
  • Home
  • Pipeline
  • Biology
  • Team
  • Investors
  • News

© 2020 APIE Therapeutics. All rights reserved

  • Privacy Policy
  • Term of Service
  • Legal info